title: CHARACTERIZING THE EFFECT OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY ON TREATMENT-NAIVE CHOROIDAL NEOVASCULARIZATION USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.
abstract: OBJECTIVE
  To use optical coherence tomography angiography (OCTA) to characterize the effects of anti-VEGF injections on treatment-naive choroidal neovascularization (CNV).
  
  
  METHODS
  From August 2014 to May 2015, treatment-naive eyes with CNV were scanned using a prototype OCTA system on a commercially available SD-OCT device (Optovue Inc, Fremont, CA). Optical coherence tomography angiography scans were obtained before anti-VEGF injection and at follow-up visits. The CNV area and greatest linear dimension (GLD) were measured along with the maximum retinal pigment epithelial detachment (RPED) height. Changes in subretinal and/or intraretinal fluid were also assessed.
  
  
  RESULTS
  Six eyes of six patients with treatment-naive CNV were included. Diagnoses included neovascular age-related macular degeneration, idiopathic polypoidal choroidal vasculopathy, CNV secondary to central serous chorioretinopathy and multifocal choroiditis, and macular telangiectasia Type 2 with subretinal neovascularization. After treatment, all patients with fluid on OCT initially showed a decrease in the amount of fluid. Five of six patients demonstrated decreases in CNV GLD and area with an average reduction of 23.6% and 29.8% respectively.
  
  
  CONCLUSIONS
  Both CNV greatest linear dimension and area measured using OCTA decreased after anti-VEGF treatment in most patients. Optical coherence tomography angiography may be a useful tool for monitoring and quantifying the response of CNV to treatment.
authors.affiliation: *New England Eye Center and Tufts Medical Center, Tufts University, Boston, Massachusetts; and †Department of Electrical Engineering and Computer Science, Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts.
authors.forename: Nora W
authors.initials: NW
authors.lastname: Muakkassa
authors.forename: Adam T
authors.initials: AT
authors.lastname: Chin
authors.forename: Talisa
authors.initials: T
authors.lastname: de Carlo
authors.forename: Kendra A
authors.initials: KA
authors.lastname: Klein
authors.forename: Caroline R
authors.initials: CR
authors.lastname: Baumal
authors.forename: Andre J
authors.initials: AJ
authors.lastname: Witkin
authors.forename: Jay S
authors.initials: JS
authors.lastname: Duker
authors.forename: Nadia K
authors.initials: NK
authors.lastname: Waheed
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002829:Choroid / Q000098:blood supply; D020256:Choroidal Neovascularization / Q000175:diagnosis* / Q000188:drug therapy; D002833:Choroiditis / Q000175:diagnosis* / Q000188:drug therapy; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D011127:Polyps / Q000175:diagnosis* / Q000188:drug therapy; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D057135:Wet Macular Degeneration / Q000175:diagnosis* / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A